SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion.
SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion.
复制标题
DOI：
10.1016/j.ophtha.2010.11.020
复制
发表时间：
2011-07
期刊：
影响因子：
13.7
通讯作者：
SCORE Study Investigator Group
中科院分区：
文献类型：
--
作者：
Chan CK;Ip MS;Vanveldhuisen PC;Oden NL;Scott IU;Tolentino MJ;Blodi BA;SCORE Study Investigator Group
在标准护理与皮质类固醇治疗视网膜静脉阻塞(SCORE)研究中，探讨：1)新生血管事件和视网膜毛细血管无灌注(简称“无灌注”)的发生率，以及它们与治疗组的关系；2)无灌注状态下的新生血管发生率；以及3)潜在新生血管事件风险的相关基线因素。两项多中心随机临床试验：一项评估视网膜中央静脉阻塞(CRVO)的参与者，另一项评估视网膜分支静脉阻塞(BRVO)的参与者。在36个月时，有81名CRVO参与者和128名BRVO参与者的数据可用。标准护理(观察或栅格光凝)与玻璃体内注射曲安奈德1毫克或4毫克。虹膜新生血管(NVI)、新生血管性青光眼(NVG)、视盘或视网膜新生血管(NVD/NVE)、视网膜前或玻璃体出血(PRH/VH)以及无灌注。CRVO和BRVO的累积36个月发生率分别为：NVI或NVG的8.5%和2.4%，NVD/NVE或PRH/VH的8.8%和7.6%。在疾病范围内比较3个治疗组，新生血管事件的发生率或无血流灌注的风险没有差异。对于36个月的CRVO，16.6%的≥5.5%的视盘无灌注区发生NVG(P=0.0003)；对于36个月的BRVO，14.6%的患者发生NVD/NVE(P<；0.0001)。无灌注是BRVO中新血管形成的唯一重要的基线因素，无灌注的椎间盘面积越大，发生新生血管事件的风险越高，并且在≥5.5时风险最高。在SCORE研究中，与观察或栅状光凝相比，曲安奈德治疗与新生血管事件或无灌注状态的发生率并不相关。大多数新生血管事件的累积36个月发生率，非灌注组显著高于灌注组。较大的无灌注基线视盘面积增加了BRVO而不是CRVO眼新生血管的风险，这可能是由于CRVO眼基线密集出血导致视网膜毛细血管细节模糊所致。在视网膜静脉阻塞的10个视盘无灌注区的历史阈值以下，新生血管的风险增加。
To investigate in The Standard Care versus COrticosteroid for REtinal Vein Occlusion (SCORE) Study: 1) incidences of neovascular events and retinal capillary nonperfusion (abbreviated as “nonperfusion”), and their relationship with treatment groups; 2) neovascular incidences by nonperfusion status; and 3) pertinent baseline factors for their potential risk for neovascular events. Two multi-center, randomized clinical trials: one evaluating participants with central retinal vein occlusion (CRVO) and the other evaluating participants with branch retinal vein occlusion (BRVO). At 36 months, data were available for 81 participants with CRVO and 128 with BRVO. Standard care (observation or grid photocoagulation) versus 1 mg or 4 mg intravitreal triamcinolone. Neovascularization of the iris (NVI), neovascular glaucoma (NVG), disc or retinal neovascularization (NVD/NVE), pre-retinal or vitreous hemorrhage (PRH/VH), and nonperfusion. Cumulative 36-month incidences for CRVO and BRVO eyes, respectively, were: 8.5% and 2.4% for NVI or NVG; 8.8 % and 7.6% for NVD/NVE or PRH/VH. There were no differences in incidences of neovascular events or risk of nonperfusion when comparing the 3 treatment groups within diseases. For CRVO at 36 months, 16.6% of eyes with ≥ 5.5 disc areas of nonperfusion vs. 4.0% of eyes with < 5.5 disc areas of nonperfusion developed NVG (P= 0.0003); for BRVO at 36 months, 14.6% versus 2.4% developed NVD/NVE (P < 0.0001). Nonperfusion was the only significant baseline factor for neovascularization in BRVO, with the risk of a neovascular event increasing with greater disc areas of nonperfusion, and the highest risk noted at ≥ 5.5 disc areas. In the SCORE Study, triamcinolone treatment was not associated with lower incidences of neovascular events or nonperfusion status compared with observation or grid photocoagulation. Cumulative 36-month incidences for most neovascular events were significantly higher for nonperfused than perfused eyes. Greater baseline disc areas of nonperfusion increased the risk of neovascularization in BRVO but not CRVO eyes, possibly due to obscuration of retinal capillary details caused by dense hemorrhage at baseline for CRVO eyes. Increased risk of neovascularization was noted below the historical threshold of 10 disc areas of nonperfusion for retinal vein occlusion.
登录
查看更多内容
影响因子：
15.9
作者：
Butler, JM;Guthrie, SM;Scott, EW
通讯作者：
Scott, EW
DOI：
10.1001/archophthalmol.2010.193
发表时间：
2010-09
期刊：
Archives of ophthalmology (Chicago, Ill. : 1960)
影响因子：
--
作者：
Blodi BA;Domalpally A;Scott IU;Ip MS;Oden NL;Elledge J;Warren K;Altaweel MM;Kim JE;Van Veldhuisen PC;SCORE Study Research Group
通讯作者：
SCORE Study Research Group
影响因子：
--
作者：
Brooks, HL;Caballero, S;Grant, MB
通讯作者：
Grant, MB
影响因子：
4.8
作者：
Nie, M;Corbett, L;Pang, LH
通讯作者：
Pang, LH
影响因子：
--
作者：
Ip, MS;Gottlieb, ML;Puliafito, CA
通讯作者：
Puliafito, CA